HC Wainwright Has Negative Estimate for AVBP FY2025 Earnings

ArriVent BioPharma, Inc. (NASDAQ:AVBP) – Analysts at HC Wainwright decreased their FY2025 earnings per share (EPS) estimates for ArriVent BioPharma in a research note issued on Tuesday, November 11th. HC Wainwright analyst R. Burns now forecasts that the company will earn ($4.32) per share for the year, down from their prior estimate of ($4.30). HC Wainwright currently has a “Buy” rating and a $42.00 target price on the stock. The consensus estimate for ArriVent BioPharma’s current full-year earnings is ($2.74) per share. HC Wainwright also issued estimates for ArriVent BioPharma’s Q4 2025 earnings at ($0.84) EPS, Q1 2026 earnings at ($0.87) EPS, Q2 2026 earnings at ($0.90) EPS, Q3 2026 earnings at ($0.93) EPS, Q4 2026 earnings at ($0.96) EPS and FY2026 earnings at ($3.65) EPS.

ArriVent BioPharma (NASDAQ:AVBP) last announced its quarterly earnings results on Monday, November 10th. The company reported ($0.83) earnings per share for the quarter, missing the consensus estimate of ($0.78) by ($0.05).

Several other research firms also recently weighed in on AVBP. Zacks Research downgraded shares of ArriVent BioPharma from a “hold” rating to a “strong sell” rating in a report on Monday, October 13th. Weiss Ratings reissued a “sell (d-)” rating on shares of ArriVent BioPharma in a research note on Wednesday, October 8th. B. Riley raised ArriVent BioPharma to a “strong-buy” rating in a research report on Monday, August 25th. Finally, Citigroup reduced their target price on shares of ArriVent BioPharma from $33.00 to $31.00 and set a “buy” rating on the stock in a report on Tuesday. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $38.86.

ArriVent BioPharma Price Performance

Shares of AVBP stock traded down $0.54 during trading on Thursday, hitting $19.66. 28,811 shares of the stock traded hands, compared to its average volume of 276,578. The firm has a market capitalization of $811.56 million, a P/E ratio of -4.64 and a beta of 1.11. ArriVent BioPharma has a 52-week low of $15.47 and a 52-week high of $32.01. The firm’s fifty day moving average price is $19.07 and its 200-day moving average price is $20.27.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Infinitum Asset Management LLC raised its stake in shares of ArriVent BioPharma by 25.7% in the 1st quarter. Infinitum Asset Management LLC now owns 2,066,238 shares of the company’s stock valued at $38,205,000 after purchasing an additional 422,315 shares in the last quarter. Moody Aldrich Partners LLC bought a new stake in ArriVent BioPharma in the second quarter valued at about $1,558,000. Nuveen LLC acquired a new stake in ArriVent BioPharma during the first quarter valued at approximately $819,000. Vanguard Group Inc. lifted its holdings in ArriVent BioPharma by 6.1% during the 1st quarter. Vanguard Group Inc. now owns 1,503,358 shares of the company’s stock worth $27,797,000 after buying an additional 86,067 shares during the last quarter. Finally, Wellington Management Group LLP boosted its holdings in ArriVent BioPharma by 46.3% in the first quarter. Wellington Management Group LLP now owns 61,348 shares of the company’s stock worth $1,134,000 after purchasing an additional 19,427 shares during the period. 9.48% of the stock is currently owned by hedge funds and other institutional investors.

About ArriVent BioPharma

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.